Harjulahti, Esa
Maaniitty, Teemu
Nammas, Wail
Stenström, Iida
Biancari, Fausto
Bax, Jeroen J.
Knuuti, Juhani
Saraste, Antti http://orcid.org/0000-0003-2488-0893
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta
Sydäntutkimussäätiö
Turun Yliopistollinen Keskussairaala
Article History
Received: 13 July 2020
Accepted: 26 October 2020
First Online: 11 November 2020
Compliance with ethical standards
:
: Dr. Saraste has received financial support from the Academy of Finland (grant number 310136), Drs. Saraste and Knuuti have been supported by the Finnish Foundation for Cardiovascular Research and State Research Funding of Turku University Hospital. Dr. Bax reports that the Department of Cardiology, Leiden University Medical Center, The Netherlands, has received unrestricted research grants from Edwards Lifescience, Medtronic, Boston Scientific, Biotronik, and GE Healthcare. Dr. Bax reports being a speaker bureau at Abbott. Dr. Knuuti reports being a speaker bureau at GE Healthcare, Merck, Lundbeck, and Bayer and consultancy fees from GE Healthcare and AstraZeneca. Dr. Saraste reports fees for lectures from Abbott, Amgen, Astra Zeneca, Bayer, and Novartis and fees for consultancy from Amgen and Astra Zenaca. Dr. Harjulahti, Dr. Stenström, Dr. Maaniitty, Dr. Biancari, and Dr. Nammas report no relationship with industry.
: The Ethics Committee of the Hospital District of Southwest Finland approved the study protocol and waived the need for informed consent by patients. The Finnish Institute for Health and Welfare gave permission to the retrospective collection of the clinical data.
: The Ethics Committee of the Hospital District of Southwest Finland waived the need for informed consent by patients.
: Not appropriate
: The Carimas software is available at ExternalRef removed